An2 Therapeutics (ANTX) closed at $4.44 on November 12, 2026, down 0.4% from the previous close, on volume of 182,393 shares (30-day average 303,689).
Data as of November 12, 2026.
12-Nov-2026
AN2 Therapeutics GAAP EPS of -$0.17
Seeking Alpha News (Mon, 9-Nov 7:48 AM ET)
Business Wire (Mon, 9-Nov 7:30 AM ET)
AN2 Therapeutics to Present at Jefferies Global Healthcare Conference in London
Business Wire (Wed, 4-Nov 4:00 PM ET)
AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)
Business Wire (Wed, 4-Nov 7:00 AM ET)
Business Wire (Mon, 2-Nov 7:00 AM ET)
AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)
Business Wire (Fri, 23-Oct 5:00 PM ET)
Business Wire (Wed, 21-Oct 7:00 AM ET)
PRNewswire (Mon, 12-Oct 8:51 AM ET)
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
Business Wire (Mon, 28-Sep 7:00 AM ET)
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
Business Wire (Wed, 16-Sep 5:33 PM ET)
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
An2 Therapeutics trades on the NASDAQ stock market under the symbol ANTX.
As of November 12, 2026, ANTX stock price declined to $4.44 with 182,393 million shares trading.
ANTX has a beta of -0.63, meaning it tends to be less sensitive to market movements. ANTX has a correlation of 0.00 to the broad based SPY ETF.
ANTX has a market cap of $168.47 million. This is considered a Micro Cap stock.
In the last 3 years, ANTX traded as high as $22.22 and as low as $.87.
The top ETF exchange traded funds that ANTX belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
ANTX has outperformed the market in the last year with a price return of +270.0% while the SPY ETF gained +12.0%. However, in the short term, ANTX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -24.4% vs -1.5% return in SPY. But in the last 2 weeks, ANTX shares have fared better than the market returning -1.8% compared to SPY -2.0%.
ANTX support price is $4.17 and resistance is $4.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANTX shares will trade within this expected range on the day.
